These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 27676695)

  • 1. Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia.
    Zin CS; Rahman NA; Ismail CR; Choy LW
    Pain Pract; 2017 Jul; 17(6):774-781. PubMed ID: 27676695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in trends and pattern of strong opioid prescribing in primary care.
    Zin CS; Chen LC; Knaggs RD
    Eur J Pain; 2014 Oct; 18(9):1343-51. PubMed ID: 24756859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of initial opioid prescription and its association with short-term and long-term use among opioid-naïve patients in Malaysia: a retrospective cohort study.
    Zin CS; Nazar NI; Rahman NSA; Ahmad WR; Rani NS; Ng KS
    BMJ Open; 2019 Jul; 9(7):e027203. PubMed ID: 31270113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study.
    Fernandes K; Martins D; Juurlink D; Mamdani M; Paterson JM; Spooner L; Singh S; Gomes T
    PLoS One; 2016; 11(12):e0167479. PubMed ID: 27973601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain.
    Ackerman SJ; Mordin M; Reblando J; Xu X; Schein J; Vallow S; Brennan M
    J Manag Care Pharm; 2003; 9(3):223-31. PubMed ID: 14613465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
    Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
    Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
    Kim DY; Song HS; Ahn JS; Ryoo BY; Shin DB; Yim CY; Kim SY
    Support Care Cancer; 2010 Feb; 19(2):297-301. PubMed ID: 20213238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
    Sittl R; Likar R; Nautrup BP
    Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
    Sittl R; Nuijten M; Poulsen Nautrup B
    Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term use of opioids in 210 officially registered patients with chronic noncancer pain in Taiwan: A cross-sectional study.
    Lin TC; Ger LP; Pergolizzi JV; Raffa RB; Wang JO; Ho ST
    J Formos Med Assoc; 2017 Apr; 116(4):257-265. PubMed ID: 28024664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.
    Corli O; Floriani I; Roberto A; Montanari M; Galli F; Greco MT; Caraceni A; Kaasa S; Dragani TA; Azzarello G; Luzzani M; Cavanna L; Bandieri E; Gamucci T; Lipari G; Di Gregorio R; Valenti D; Reale C; Pavesi L; Iorno V; Crispino C; Pacchioni M; Apolone G;
    Ann Oncol; 2016 Jun; 27(6):1107-1115. PubMed ID: 26940689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative out-of-hospital mortality of long-acting opioids prescribed for non-cancer pain: A retrospective cohort study.
    Chung CP; Dupont WD; Murray KT; Hall K; Stein CM; Ray WA
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):48-53. PubMed ID: 30003613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of opioid use for chronic noncancer pain in the Veterans Health Administration from 2009 to 2011.
    Edlund MJ; Austen MA; Sullivan MD; Martin BC; Williams JS; Fortney JC; Hudson TJ
    Pain; 2014 Nov; 155(11):2337-43. PubMed ID: 25180008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
    Matsuoka H; Tsurutani J; Chiba Y; Fujita Y; Terashima M; Yoshida T; Sakai K; Otake Y; Koyama A; Nishio K; Nakagawa K
    BMC Cancer; 2017 Oct; 17(1):674. PubMed ID: 28985716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
    Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
    Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Only modest long-term opioid dose escalation occurs over time in chronic nonmalignant pain management.
    Chapman CR; Bradshaw DH
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):370-7. PubMed ID: 24143927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Quality of Life of Cancer Patients with Pain Treated with Oral Controlled-Release Morphine and Oxycodone and Transdermal Buprenorphine and Fentanyl.
    Leppert W; Nosek K
    Curr Pharm Des; 2019; 25(30):3216-3224. PubMed ID: 31333114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.